Get the Stockscreener App
0.208
4.59%
-0.01
China Pharma Holdings Inc. stock is traded at $0.208, with a volume of 1.00M.
It is down -4.59% in the last 24 hours and down -3.70% over the past month.
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, cephalosporin oral solutions, and granules. The company's products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Anhydroandrographolide for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; and Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. is headquartered in Haikou, the People's Republic of China.
See More
Previous Close:
$0.218
Open:
$0.22
24h Volume:
1.00M
Relative Volume:
1.19
Market Cap:
$4.00M
Revenue:
$5.54M
Net Income/Loss:
$-4.74M
P/E Ratio:
-0.619
EPS:
-0.336
Net Cash Flow:
$-750.60K
1W Performance:
-3.70%
1M Performance:
-3.70%
6M Performance:
+2.87%
1Y Performance:
-58.40%
1-Day Range:
$0.18
$0.2202
1-Week Range:
$0.18
$0.24
52-Week Range:
$0.13
$0.49
China Pharma Holdings Inc. Stock (CPHI) Company Profile
Name
China Pharma Holdings Inc.
Sector
Phone
86 898 6681 1730
Address
No. 17, Jinpan Road, Second Floor, Haikou
Compare CPHI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPHI
China Pharma Holdings Inc.
|
0.208 | 4.00M | 5.54M | -4.74M | -750.60K | -0.336 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
China Pharma Holdings Inc. Stock (CPHI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-10 | Initiated | Rodman & Renshaw | Mkt Outperform |
China Pharma Holdings Inc. Stock (CPHI) Latest News
Hong Kong Pharma Digital Technology Holdings Limited Partners with Leading Chinese E-commerce Platform to Enhance Cross-Border Logistics Services - PR Newswire
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA - PR Newswire
InnoCare Pharma receives approval for CLL/SLL combination therapy trial in China - Yahoo
China Pharma (NYSE:CPHI) Coverage Initiated by Analysts at StockNews.com - Defense World
Is Pfizer Inc. (PFE) the Best Drug Stock to Buy Now? - Yahoo Finance
Why AbbVie Inc. (ABBV) Is One of the Best Drug Stocks to Buy Now - Yahoo Finance
U.S. investors, Big Pharma race to find new medicines in China - MSN
Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits - Quantisnow
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025 - Quantisnow
China Pharma (NYSE:CPHI) Now Covered by StockNews.com - Defense World
Hong Kong Stock Exchange Companies List - Morningstar.com.au
Layoff Tracker: Viracta, X4 and BMS Detail Current, Upcoming Cuts - BioSpace
China Pharma Holdings Inc (CPHI) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Post-Trade Analysis: China Pharma Holdings Inc (CPHI) Slides -7.63, Closing at 0.21 - The Dwinnex
Closing Bell Recap: International Paper Co (IP) Ends at 53.89, Reflecting a -3.47 Downturn - The Dwinnex
Big Pharma is staying quiet on Trump's China tariffs - Yahoo Finance
China Medical System Holdings Limited (HKG:867) insiders have significant skin in the game with 52% ownership - Simply Wall St
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by China Universal Asset Management Co. Ltd. - MarketBeat
China Universal Asset Management Co. Ltd. Acquires 8,018 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by China Universal Asset Management Co. Ltd. - MarketBeat
China Pharma (NYSE:CPHI) Now Covered by Analysts at StockNews.com - Defense World
Pharmaceuticals Wholesale and Distribution Market to grow by USD 896.5 Billion (2024-2028), driven by rising global pharmaceutical sales, Report on how AI is redefining market landscapeTechnavio - Yahoo Finance
China NT Pharma Group to Hold Extraordinary General Meeting for New Share Subscription Approval - TipRanks
China Pharma (NYSE:CPHI) Earns Hold Rating from Analysts at StockNews.com - Defense World
Ascentage Pharma Prices U.S. IPO At $17.25/ADS - RTTNews
Asia Hedge Funds Post Biggest Annual Returns Since the Pandemic - Bloomberg
Henlius Biotech shareholders reject take-private offer from China's Fosun - Reuters.com
Tariff threats, drug pricing will be 2 key pharma issues during Trump's first year - Yahoo Finance
‘The bar has risen’: China’s biotech gains push US companies to adapt - BioPharma Dive
Ascentage Pharma Group International (OTCMKTS:ASPHF) Short Interest Update - Defense World
The top 10 biopharma M&A deals of 2024 - FiercePharma
Dry Eye Products Market Opportunities and Strategies to - GlobeNewswire
Li Ka-Shing-Backed Hutchmed Sells Stake in Unit for $608 Million - MSN
Barclays PLC Has $759,000 Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
StockNews.com Begins Coverage on China Pharma (NYSE:CPHI) - Defense World
China Pharma Holdings, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019 - Marketscreener.com
China Pharma Holdings, Inc. Rescinds Securities Purchase Agreement - Defense World
PetVivo Holdings, Inc. to Make Investor Presentations - Defense World
Keen Vision Acquisition Extends Business Combination PeriodKeen Vision Acquisition Corporation (NASDAQ: KVAC) has recently filed a Form 8-K with the Securities and Exchange Commission, announcing the extension of its business combination period. T - Defense World
AmpliTech Group Enters Securities Purchase Agreement with Institutional InvestorsWASHINGTON, D.C., December 24, 2024 – AmpliTech Group, Inc. (NASDAQ: AMPG) disclosed today in an 8-K filing with the Securities and Exchange Commission that it has - Defense World
Blackboxstocks Inc. Dismisses Turner, Stone & Company as Independent Registered Public Accounting Firm; Engages Victor Mokuolo CPA PLLC as ReplacementOn December 20, 2024, Blackboxstocks Inc. (NASDAQ: BLBX) made significant changes in its a - Defense World
The Glimpse Group Announces Closing of $7.29 Million OfferingWASHINGTON, D.C., December 23, 2024 – The Glimpse Group, Inc. (NASDAQ:VRAR) disclosed the finalization of a registered direct offering on December 23, 2024. The undertaking involved a - Defense World
Creative Medical Technology Holdings, Inc. Reports Amendment to Articles of Incorporation and Voting Results Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) filed a Form 8-K with the Securities and Exchange Commission on December 19, 20 - Defense World
Analysts Set Celsius Holdings, Inc. (NASDAQ:CELH) Price Target at $50.28 - Defense World
China Pharma Holdings, Inc. Successfully Conducts Annual Stockholders’ Meeting - Defense World
GlycoMimetics Receives Extension Notice from Nasdaq Regarding Minimum Bid Price ComplianceOn December 19, 2024, GlycoMimetics, Inc. (NASDAQ: GLYC) disclosed in an 8-K filing with the Securities and Exchange Commission that it had received an e - Defense World
**Rhinebeck Bancorp Completes Balance Sheet Repositioning, Projects Earnings Growth** - Defense World
Wrap Technologies Reports Approval of Incentive Plan Amendment and Director Elections at Annual Meeting - Defense World
Financial Review: Autozi Internet Technology (Global) (NASDAQ:AZI) vs. Driven Brands (NASDAQ:DRVN) - Defense World
Aker BP ASA (OTCMKTS:AKRBF) Trading Down 1.7% – Here’s What Happened - Defense World
Edesa Biotech, Inc. (NASDAQ:EDSA) Short Interest Update - Defense World
China Pharma Holdings Inc. Stock (CPHI) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.23%
3.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):